Biomarker modeling of alzheimer's disease

Clifford R Jr. Jack, David M. Holtzman

Research output: Contribution to journalArticle

389 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

Original languageEnglish (US)
Pages (from-to)1347-1358
Number of pages12
JournalNeuron
Volume80
Issue number6
DOIs
StatePublished - Dec 18 2013

Fingerprint

Alzheimer Disease
Biomarkers
Amyloid Plaques
Age of Onset
Cerebrospinal Fluid
Pathology
Brain

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Biomarker modeling of alzheimer's disease. / Jack, Clifford R Jr.; Holtzman, David M.

In: Neuron, Vol. 80, No. 6, 18.12.2013, p. 1347-1358.

Research output: Contribution to journalArticle

Jack, Clifford R Jr. ; Holtzman, David M. / Biomarker modeling of alzheimer's disease. In: Neuron. 2013 ; Vol. 80, No. 6. pp. 1347-1358.
@article{aa035436d175405dbb21aec6f055dd0c,
title = "Biomarker modeling of alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.",
author = "Jack, {Clifford R Jr.} and Holtzman, {David M.}",
year = "2013",
month = "12",
day = "18",
doi = "10.1016/j.neuron.2013.12.003",
language = "English (US)",
volume = "80",
pages = "1347--1358",
journal = "Neuron",
issn = "0896-6273",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Biomarker modeling of alzheimer's disease

AU - Jack, Clifford R Jr.

AU - Holtzman, David M.

PY - 2013/12/18

Y1 - 2013/12/18

N2 - Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

AB - Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

UR - http://www.scopus.com/inward/record.url?scp=84890528022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890528022&partnerID=8YFLogxK

U2 - 10.1016/j.neuron.2013.12.003

DO - 10.1016/j.neuron.2013.12.003

M3 - Article

AN - SCOPUS:84890528022

VL - 80

SP - 1347

EP - 1358

JO - Neuron

JF - Neuron

SN - 0896-6273

IS - 6

ER -